Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyVax + GM-CSF in Previously Untreated B-CLL
NCT00302861Phase 2Terminated
- Sponsor
- Genitope Corporation
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label, single-arm trial of MyVax in chronic lymphocytic leukemia (CLL), sponsored by Genitope Corporation. Primary endpoints: The proportion of patients with positive humoral immune responses and Safety and toxicity. Started Mar 2006; status: terminated.
02
Drugs
MyVax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00302861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302861.